CalciMedica Presents Promising Data on Auxora for AKI
CalciMedica Inc. has recently shared significant findings from a preclinical study on Auxora™, highlighting its potential impact on treating acute kidney injury (AKI). The study shows that treatment with Auxora significantly diminished IL-17-related inflammation in both the kidney and lung. Furthermore, it led to a substantial increase in glomerular filtration rate (GFR) while reducing renal injury in a rat model of AKI.
This promising data supports the rationale for employing Auxora in the treatment of severe AKI, particularly in patients experiencing respiratory failure. Currently, the efficacy of Auxora is under evaluation in the ongoing Phase 2 KOURAGE trial.
Insights from the Preclinical Study
The study was conducted on rat models suffering from ischemia/reperfusion (I/R)-induced AKI. The research team administered either Auxora™ at a dose of 16 mg/kg or a placebo three times at intervals of 6, 24, and 48 hours post-I/R injury. The assessment of GFR was repeated at the 72-hour mark to evaluate how Auxora impacted renal function after an established decline in GFR. An additional examination involving flow cytometry was performed to analyze immune cell subsets present in both the kidney and lung tissues.
Key Findings of the Study
The research revealed several noteworthy outcomes:
- Auxora treatment reduced the levels of Th-17 cells in the kidney by an impressive 64% compared to the placebo group (p<0.05), aligning with previous results showing a 50% drop in these cells after a single drug dosage (p<0.05).
- In the lung, treatment with Auxora led to a 59% reduction in Th-17 cells and a significant 69% reduction in IL-6-producing CD4 cells (each p<0.05).
- Kidneys treated with Auxora showed marked improvement at the 72-hour checkpoint, indicated by a greater recovery in GFR (p?0.01) and optimized serum creatinine levels (p<0.05) when compared to the placebo.
- Histological assessments revealed that Auxora-treated subjects exhibited substantially reduced kidney necrosis and more than 50% less tubular injury than those receiving the placebo.
These findings offer compelling evidence supporting the use of Auxora as a treatment option for patients suffering from severe AKI and acute hypoxemic respiratory failure (AHRF). Critically ill patients with severe AKI typically present with elevated IL-17 levels that are associated with poor prognosis. The interplay between IL-17 levels and lung-kidney interactions suggests that managing this cytokine could be crucial in preventing multi-organ failure.
Expert Commentary on the Findings
Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica stated, "The data presented enhances our understanding of CRAC channel inhibition as a valuable strategy to modulate inflammatory responses and reduce tissue injury in cases of AKI and other critical illnesses." With the Phase 2 KOURAGE trial nearing its pivotal outcomes, the accumulating evidence positions Auxora as a potentially transformative therapy capable of addressing significant unmet medical needs in critically ill populations.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical venture that specializes in pioneering therapies based on novel calcium release-activated calcium (CRAC) channel inhibition for inflammatory and immunological conditions. The proprietary technology of CalciMedica is designed to regulate immune responses and offer protection against cellular damage associated with various inflammatory and immune diseases. Their lead product candidate, Auxora™, has yielded consistently positive clinical results across multiple trials, showing good tolerability in over 350 critically ill individuals. The company is also conducting other clinical trials including CARPO and CARDEA, which address conditions such as acute pancreatitis and respiratory complications tied to COVID pneumonias.
Frequently Asked Questions
What is the main finding from CalciMedica's preclinical study on Auxora?
The study found that Auxora significantly reduces IL-17-related inflammation, improves kidney function, and mitigates renal injury in rats with AKI.
What are the implications of these findings for AKI patients?
These findings suggest that Auxora may offer a promising treatment avenue for severe AKI, particularly for patients facing respiratory failure.
How does Auxora operate on a cellular level?
Auxora functions by inhibiting CRAC channels, which plays a critical role in modulating the immune response and reducing tissue injury.
When will the results of the Phase 2 KOURAGE trial be available?
While a specific date is not mentioned, results from the trial are anticipated as the study progresses further.
Are there any ongoing trials associated with CalciMedica?
Yes, CalciMedica is currently engaged in various clinical trials, including the ongoing Phase 2 trials for Auxora targeting different inflammatory conditions.
